Background. In human immunodeficiency virus (HIV)-infected patients, hepatitis B virus (HBV) coinfection increases the risk of disease progression. Tenofovir plus emtricitabine/lamivudine (TDF/XTC)-based antiretroviral therapy (ART), which suppresses HIV and HBV replication, has the potential for decreasing this risk. Here, we analyze the association between HBV replication, early ART, and mortality in West African adults.
Sub-Saharan Africa has the highest prevalence of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection compared to the rest of the world [1] . In this setting, HBV infection predominately occurs during early childhood [2] . Chronic HBV infection affects 5%-10% of the overall population, with similar prevalence in HIV-infected and uninfected individuals [3] . This prevalence is worrying as diagnosis of HBV infection is frequently delayed and liver-related medical services are limited [4] .
In HIV-infected patients, HBV coinfection increases the rate of morbidity and mortality [5] . Tenofovir + emtricitabine or lamivudine (TDF/XTC)-based antiretroviral therapy (ART), which suppresses both HIV and HBV replication, could counterbalance this association. Studies in HIV-infected individuals from sub-Saharan Africa have observed increased risk of allcause mortality for those with HBV coinfection despite initiating ART [6] [7] [8] . Nevertheless, most of these studies used ART regimens with less-potent anti-HBV agents [5] and included severely immunocompromised patients who are prone to AIDS-related disease and poor immune recovery [9, 10] . Whether increased risk of death is also observed in coinfected patients initiating TDF/XTC-based ART at higher CD4 + T-cell counts is unknown. Additionally, there are limited data regarding the influence of ART timing on disease outcomes in coinfected patients. In 2008-2015, we conducted a randomized controlled trial to
M A J O R A R T I C L E
assess the benefits of TDF/XTC-based immediate ART and 6-month isoniazid preventive therapy (IPT) for tuberculosis in HIV-infected adults with high CD4 counts in Côte d'Ivoire, West Africa. The trial endpoint was severe morbidity at 30 months. The final analysis showed that immediate ART led to lower rates of severe morbidity than deferred ART [11] . After participants reached 30 months of follow-up in the trial, they continued follow-up in a posttrial phase. Here, we present results of an analysis on the association between HIV/HBV coinfection, immediate ART, and all-cause mortality at the end of the posttrial phase.
METHODS

Participants and Study Design
All participants in the Temprano ANRS 12136 trial were eligible for updated analysis. Participants with missing data on plasma hepatitis B surface antigen (HBsAg) and HBsAg-positive participants with missing data on plasma HBV DNA levels were excluded.
The Temprano trial was a randomized controlled, 2 × 2 factorial, superiority trial, conducted in 9 clinics in Côte d'Ivoire. The trial design and results have been previously reported [11] . In summary, from March 2008 to July 2012, patients were included based on the following criteria: HIV infection, ≥18 years of age, CD4 count <800 cells/μL, absence of active tuberculosis or severe liver disease, and no criteria for starting ART according to the most recent World Health Organization (WHO) guidelines (2006 guidelines [12] from trial start to November 2009, 2010 guidelines [13] from December 2009 to July 2013, and 2013 guidelines [14] from August 2013 to end of trial). Liver-related exclusion criteria were as follows: plasma aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels >4 times the upper limit of normal or any other severe liver disease.
Trial Arms and Treatment
Participants were randomly assigned to 1 of 4 arms: 2 "deferred ART" arms (arms 1 and 2), in which ART initiation was deferred until patients met concurrent WHO starting criteria; and 2 "immediate ART" arms (arms 3 and 4), in which ART was initiated immediately at inclusion. In arms 2 and 4, participants received 6-month isoniazid prophylaxis for tuberculosis. First-line ART regimen contained TDF/emtricitabine with the third agent preferably efavirenz or, if contraindicated, zidovudine or lopinavir/ritonavir.
Follow-up
All participants in the Temprano trial were followed for 30 months. The first Temprano study participant completed 30 months of follow-up in September 2010. From this date, all patients who reached the 30-month visit were asked to continue follow-up in a posttrial phase (PTP) until the last patient completed their 30-month trial visit (closing date: 5 January 2015). Both the Temprano study and PTP had similar procedures: patients had quarterly visits at their healthcare center and were requested to present for additional visits any time they encountered a medical event; CD4 count and plasma HIV type 1 (HIV-1) RNA were measured every 6 months; consultations, CD4 count, viral load, and antiretroviral drugs were free of charge; and patients who did not present at a trial visit were traced by experienced social workers. Patients assigned to the deferred ART arms who had not started ART during the trial commenced ART during the PTP whenever they reached the most recent ART-initiation WHO criteria. Patients who did not reach WHO criteria before the closing date did not commence ART, be it during the trial or PTP.
There were 2 differences between the Temprano study and PTP. First, transportation for unscheduled visits, consultations, hospitalization, and nonantiretroviral drugs were free of charge when morbidity events occurred during the trial. In PTP, patients were required to pay out-of-pocket, similar to other patients followed in routine care at the same center. Second, the primary outcome was severe morbidity (including all-cause mortality) in the Temprano trial and only all-cause mortality in the PTP.
Study Parameters
All participants had a chest radiograph at inclusion. Blood tests including CD4 count, plasma HIV-1 RNA, and serum aminotransferases were done at baseline and every 6 months.
HBsAg serology was performed at baseline using an enzymelinked immunosorbent assay (Monolisa Bio-Rad, Marnes la Coquette, France). From frozen samples stored at -80°C, hepatitis B "e" antigen (HBeAg), and anti-HBe antibodies (antiHBeAb) were detected at baseline using the Elecsys assay (Roche Diagnostics, Meylan, France). HBV DNA viral loads were quantified at baseline using an in-house polymerase chain reaction (PCR)-based assay (QuantiFast SYBR Green PCR kit, detection limit: 12 copies/mL; Qiagen, Courtaboeuf, France; Light Cycler 480; Roche, Boulogne-Billancourt, France) [15] or a commercially available PCR assay (COBAS Amplicor HBV Monitor, detection limit: 60 IU/mL; Roche Diagnostics, Meylan, France). To ensure comparability between assays, viral loads were reported in international units per milliliter (conversion factor: 1 IU/mL = 2.8 copies/mL [16] ).
Statistical Analysis
The primary endpoint was all-cause mortality. The secondary endpoint was death or loss to follow-up (LTFU). LTFU was defined by whether patients did not attend their last quarterly scheduled visit and no further information on their vital status was available within the 6 months preceding the closing date.
Patients were grouped as HIV monoinfected (all HBsAg-negative participants) or HIV/HBV coinfected (all HBsAg-positive participants), the latter of which was further stratified on plasma HBV DNA <2000 IU/mL (low HBV viral load) and plasma HBV DNA ≥2000 IU/mL (high HBV viral load) at inclusion. The threshold of 2000 IU/mL was chosen based on levels corresponding to active infection and treatment indication among HBV-monoinfected individuals [17] . Mantel-Haenszel χ 2 or Fisher exact tests were used to compare baseline characteristics between these groups. The distribution of continuous variables was compared using Kruskal-Wallis test. While stratifying on these groups, we used the Kaplan-Meier method to estimate the cumulative probability of death and death or LTFU, and estimated the incidence rates by dividing the number of first events by cumulative time at-risk. The time at-risk began at randomization and ended at death, LTFU, or 5 January 2015, whichever occurred first.
Cox proportional hazards models were used to compare hazards of achieving each endpoint between HBsAgnegative and HBsAg-positive patients (2-group analysis), and between HBsAg-negative, HBsAg-positive patients with HBV DNA <2000 IU/mL, and HBsAg-positive patients with HBV DNA ≥2000 IU/mL (3-group analysis). In multivariable analysis, hazard ratios (HRs) were adjusted a priori for the following variables: Temprano ART strategy (immediate vs deferred ART), Temprano IPT strategy (IPT vs no IPT), baseline CD4 cell count, sex, and baseline plasma HIV-1 RNA. Interactions between variables were tested. The proportional hazards assumption was examined.
All reported P values were 2-sided and no adjustments for multiple comparisons were applied. Statistical analyses were performed with SAS 9.4 software (SAS Institute, Cary, North Carolina).
Funder, Registration, and Ethics
The Temprano trial protocol, which included the PTP, was approved by the Côte d'Ivoire National Ethics Committee for Health Research. It was registered at ClinicalTrials.gov (NCT00495651). Signed informed consent was provided prior to participating in the trial and PTP. The sponsor had no role in the conduct of the study or interpretation of the data.
RESULTS
Baseline and Follow-up Characteristics
Overall
Of the 2056 participants analyzed in the Temprano trial, 2052 (99.8%) were included in this updated analysis. Median CD4 count was 464 (interquartile range [IQR], 369-573) cells/μL and median plasma HIV RNA was 4.7 (IQR, 4.0-5.3) log 10 copies/mL. Five hundred sixteen patients were randomized to immediate ART and IPT, 514 to immediate ART and no IPT, 511 to deferred ART and IPT, and 511 to deferred ART and no IPT. There was no difference in baseline characteristics between arms.
Total follow-up time was 9394 person-years (PY), with a median of 58.3 (IQR, 40.3-68.9) months per participant. At study closing date, 1830 (89%) participants had started ART (including 1030 at baseline and 800 during follow-up). The cumulative time spent on ART was 7136 PY, accounting for 76% of the total follow-up time. The percentage of treated patients who declared having missed ≥ 1 antiretroviral drug intake during the previous 4 days anytime between study visits was 73% (n = 1313/1796).
By Hepatitis B Virus Status
At baseline, 1862 (91%) patients were HIV monoinfected and 190 (9%) HIV/HBV coinfected. Of the latter, 135 (71%) had plasma HBV DNA <2000 IU/mL (including 64 with undetectable HBV DNA) and 55 (29%) had HBV DNA ≥2000 IU/ mL ( Figure 1 and Table 1 ). Compared to patients with HIV monoinfection, coinfected patients were more frequently male (13% vs 8% female; P = .003). Coinfected patients with HBV DNA ≥2000 IU/mL tended to have higher HIV RNA viral load, lower CD4 count, and higher rates of abnormal plasma ALT values compared with other patients. There was no difference between HBsAg-negative and HBsAg-positive patients in terms of follow-up time, proportion initiating ART, and time spent on ART (Table 1) .
Among patients who received ART once during follow-up, the percentage who declared having missed ≥1 antiretroviral drug intake during the previous 4 days anytime between study visits was 73% in HIV monoinfection (n = 1188/1627), 74% in coinfection with low HBV DNA viral loads (n = 89/120), and 73% in coinfection with high HBV DNA viral loads (n = 36/49) (P = .96).
Outcomes
At study closing date, 1760 participants were alive and in active follow-up, 206 were lost to follow-up, and 86 were known to have died. Of the 86 deaths, 47 (54.6%) occurred during the trial and 39 (45.4%) during the PTP. Of the 206 lost to follow-up, 57 (27.7%) occurred during the trial and 149 (72.3%) during the PTP (Figure 1 ). The number of deaths was 74 (4.0%) in HIV-monoinfected patients, 5 (3.7%) in HIV/HBVcoinfected patients with low HBV DNA, and 7 (12.7%) in HIV/ HBV-coinfected patients with high HBV DNA. The number lost to follow-up was 183 (9.8%) in HIV-monoinfected patients, 15 (11.1%) in HIV/HBV-coinfected patients with low baseline HBV DNA, and 8 (14.5%) in HIV/HBV-coinfected patients with high baseline HBV DNA (Table 1) .
A total of 25 causes of death were documented. Documented causes of death included tuberculosis (n = 8), cancer (n = 5), bacterial diseases (n = 3), renal insufficiency (n = 3), cardiovascular diseases (n = 2), cryptococcosis (n = 1), firearm injury (n = 1), and liver diseases (n = 2). The lattermost cause of death included 1 case of liver cirrhosis in an HBsAg-negative patient who died after 39 months of follow-up and spent 6 months on ART, and another case of fulminant hepatitis in an HBsAgpositive patient with high baseline HBV DNA. This patient was randomized to deferred ART and no IPT. Death occurred 84 days after inclusion and was due to cotrimoxazole-related toxicity.
Association Between Outcomes, Hepatitis B Virus Status, and Early Antiretroviral Therapy
In univariable analysis, the risk of death and of death or LTFU was similar in HIV-monoinfected and -coinfected patients with low HBV DNA viral load, and significantly higher in coinfected patients with high HBV DNA viral load (hazard ratio Table 2 ). There was no interaction between ART strategy and HBV status for mortality (P = .9). These results were unchanged in sensitivity analysis including cotrimoxazole as a time-dependent covariate in the multivariable model (data not shown).
Overall, the 60-month probability of death was 11.8% (95% CI, 5.4%-24.5%) in coinfected patients with high HBV DNA viral load, 4.4% (95% CI, 1.9%-10.4%) in coinfected patients with low HBV DNA viral load, and 4.2% (95% CI, 3.3%-5.4%) in HIV-monoinfected patients (Figure 2A) . The 60-month probability of death or LTFU was 26.6% (95% CI, 16.3%-41.7%) in coinfected patients with high HBV DNA viral load, 16.8% (95% CI, 11.0%-25.3%) in coinfected patients with low HBV DNA viral load, and 14.1% (95% CI, 12.4%-16.0%) in HIV-monoinfected patients ( Figure 2B ). When considering only patients randomized to immediate ART, the 60-month probability of death was 13.7% (95% CI, 4.6%-37.2%), 4.7% (95% CI, 1.5%-13.9%), and 3.6% (95% CI, 2.5%-5.3%) in coinfected patients with high HBV DNA viral load, coinfected patients with low HBV DNA viral load, and HIVmonoinfected patients, respectively. When considering only patients randomized to deferred ART, the 60-month probability of death was 10.3% (95% CI, 3.4%-28.6%), 4.0% (95% CI, 1.0%-15.5%), and 4.8% (95% CI, 3.5%-6.6%) in coinfected patients with high HBV DNA viral load, coinfected patients with low HBV DNA viral load, and HIV-monoinfected patients, respectively (Figure 3 ).
DISCUSSION
In this large trial assessing the benefits of early ART in West African HIV-infected adults, we found a higher risk of mortality in HIV/HBV-coinfected patients with high HBV DNA viral loads compared to other patients. Similar findings have been observed in previous observational studies with an average follow-up of up to 2 years [5, 18] . We extend these findings to a median of 55 months. Among 125 patients (missing data, n = 65). c Two hundred twenty-two patients never started ART because their CD4 cell count remained >500 cells/μL during the entire follow-up. Main ART regimen was TDF-FTC + EFV. Among the 80 patients who started ART with TDF-FTC + LPV/r, the reason for not receiving an EFV-based regimen was dual HIV-1/2 infection, previous nevirapine use for preventing mother-to-child transmission, declining to use effective contraception, and other. e Other regimens were TDF-FTC-zidovudine (ZDV) (n = 81), ZDV-lamivudine (3TC)-LPV/r (n = 29), ZDV-3TC-nevirapine (n = 15), ZDV-3TC-EFV (n = 8), didanosine-3TC-EFV (n = 2), 3TC-abacavir-LPV/r (n = 2), stavudine (D4T)-3TC-EFV (n = 1), D4T-3TC-LPV/r (n = 1), TDF-FTC-nevirapine (n = 1), and TDF-FTC-3TC-D4T (n = 1). f One hundred three patients did not take IPT. Reasons for not starting IPT were the presence of signs suggestive of tuberculosis on chest radiographs obtained at baseline (n = 16), presence of clinical signs suggestive of tuberculosis at the 1-month visit (n = 47), nonattendance at the 1-month visit (n = 24), elevated aminotransferase levels at baseline (n = 6), pregnancy (n = 4), death before 1 month (n = 1), and other (n = 5). g Reasons for stopping IPT prematurely were death from an unknown cause (n = 1), discontinuation by patients for personal, nonmedical reasons (n = 22), discontinuation by physician because of signs or symptoms suggestive of tuberculosis (n = 10, 3 of whom were later confirmed to have tuberculosis), pregnancy (n = 13), and the following adverse events (n = 12): elevated aminotransferase levels, psychiatric side effects, and pruritus. None of the episodes of elevated aminotransferase levels led to death.
In our trial, first-line ART included tenofovir and emtricitabine. This combination is ideal for HIV/HBV-coinfected patients due to its potent anti-HIV and anti-HBV activity [5, 19] . As coinfected patients with high HBV DNA and HIV RNA replication continue without antiviral treatment, their risk for liver-related complications increases [20] . Furthermore, greater HBV replication affects immune function [21] , which potentially leads to increased risk of non-liver-related complications [22] . Therefore, it could be expected that initiating ART earlier would provide coinfected patients with an increased benefit in terms of mortality reduction. This was not what we observed. In our study, the higher rate of mortality was maintained after adjusting for ART strategy, while the 60-month probability of death appeared similar in patients randomized to immediate ART or deferred ART, particularly in the subgroup of coinfected patients with high HBV viral load. These findings suggest that other strategies should be combined with early ART to reduce mortality in patients with high HBV replication [23] .
Higher mortality rates in coinfected patients have been observed in several studies from the United States and Tanzania [24] [25] [26] . Some previous studies have suggested that death due to liver disease could increase in the ART era because of the decrease in HIV-related diseases [27] . Recent reports from the United States and Europe have indeed shown increased mortality related to liver disease in HIV/HBV-coinfected patients [26, 28] . However, other research, such as in the French mortality 2000 study, have suggested that AIDS-related diseases remain a frequent cause of death in coinfected patients [10, 27] , highlighting the role of HBV infection in increased HIV virulence and acceleration towards AIDS [6] . The main differing characteristics of these studies compared to our trial, besides geographical location, were the extent of severe immunosuppression (with median CD4 + T-cell counts ranging from 200 to 250 cells/μL) and longer follow-up periods. In our study, the most frequently documented causes of death were HIV-related infections or tumoral diseases. However, because of the high rate of undocumented causes and lack of liver fibrosis assessment, our data do not add to the debate on the preponderance of HIV-and HBV-related diseases attributing to death among coinfected patients. Causes of deaths are oftentimes difficult to document in trials enrolling HIV-infected individuals and conducted in limited-resource countries, where the majority of patients die at home or in hospital settings with inadequate facilities to document morbidity compared to those . ART strategy, sex, and baseline CD4 count were not significantly associated with mortality. There was no statistical evidence that these associations were different across HBV infection groups (P value for interaction: HIV RNA = .49; CD4 cell count = .93).
in resource-rich countries. Furthermore, follow-up was not frequent enough to document the incidence of hepatic diseases, compared to other cohorts [29] . Finally, patients with severe liver diseases or high aminotransferase levels were not included in the Temprano trial, which likely diminished the risk of mortality from liver diseases. Our study has several other limitations. First, HCV infection was not documented. However, its prevalence was probably low in the overall trial population, and even lower in HIV/HBVcoinfected patients [30] . Second, we did not document occult HBV infection. The risk of liver-related disease and mortality is purportedly similar in HBsAg-negative patients with occult HBV infection and HBsAg-positive patients with low HBV DNA viral load. The inability to document occult HBV infection would, therefore, likely have no impact on our main result [31] . Third, 34% of HBsAg-positive patients had missing data on HBeAg serology. Fourth, healthcare was free of charge when morbidity events occurred during the Temprano trial, whereas patients had to pay out-of-pocket during similar events in the posttrial phase. LTFU could have increased, thereby underestimating mortality rates during the posttrial phase. However, follow-up time and percentage of patients with LTFU were similar in HIV-monoinfected patients and coinfected patients with high or low HBV DNA levels. It is then unlikely that mortality was more frequently underestimated in one group compared to others. Finally, we lacked longitudinal HBV and HIV virologic data, including data on resistant variants. It should be mentioned, however, that 97% of coinfected participants undergoing ART received a tenofovir-containing regimen and no study to date has identified HBV variants resistant to this agent [19] .
In conclusion, sub-Saharan African HIV-infected adults with chronic hepatitis B remain a population at heightened risk of mortality in the ART era, even for those at an early stage of HIV infection. Further studies are needed to assess whether other interventions should be combined with early ART to decrease mortality in HIV/HBV-coinfected patients with high HBV DNA viral load. Considering that HIV and HBV infections are acquired at different timepoints in life, early ART for HIV is not tantamount to early antiviral treatment for HBV. It would be recommended to treat HBV-monoinfected patients demonstrating active replication prior to becoming coinfected, noting that tenofovir use could additionally protect against HIV infection. Figure 3 . Probability of death, according to hepatitis B virus (HBV) status and antiretroviral therapy (ART) strategy. Cumulative probability calculated by the Kaplan-Meier method is depicted for death, while stratifying on human immunodeficiency virus (HIV) monoinfected, HIV/HBV coinfected with HBV DNA viral load <2000 IU/mL, and HIV/ HBV coinfected with HBV DNA viral load ≥2000 IU/mL; and for immediate and deferred ART within each of these groups. Log-rank P values for immediate vs deferred ART: among HBsAg-negative patients, P = .16; among HBsAg-positive patients with HBV DNA <2000 IU/mL, P = .92; among HBsAg-positive patients with HBV DNA ≥2000 IU/mL, P = .93. Abbreviations: ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IU, international units.
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